Validating a Proteomic Signature of Severe COVID-19.

ABSTRACT: COVID-19 is a heterogenous disease. Biomarker-based approaches may identify patients at risk for severe disease, who may be more likely to benefit from specific therapies. Our objective was to identify and validate a plasma protein signature for severe COVID-19.

Design

Prospective observational cohort study.

Setting

Two hospitals in the United States.

Patients

One hundred sixty-seven hospitalized adults with COVID-19.

Intervention

None.

Measurements and main results

We measured 713 plasma proteins in 167 hospitalized patients with COVID-19 using a high-throughput platform. We classified patients as nonsevere versus severe COVID-19, defined as the need for high-flow nasal cannula, mechanical ventilation, extracorporeal membrane oxygenation, or death, at st

SUBMITTER: Cosgriff CV 

PROVIDER: S-EPMC9722553 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature